Correction (DOI:10.1016/j.jaci.2009.03.032);Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 5, 2009, Pages 1124-1133

  Jensen, Jens Michael ^a   Pfeiffer, Stephan ^b   Witt, Magdalena ^a   Bräutigam, Matthias ^c   Neumann, Claudia ^a   Weichenthal, Michael ^a   Schwarz, Thomas ^a   Fölster Holst, Regina ^a   Proksch, Ehrhardt ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Microscopy Services   (Germany)

^c Novartis Pharma GmbH   (Germany)

Author keywords

Atopic dermatitis; corticosteroid; pimecrolimus; skin barrier; skin penetration

Indexed keywords

BETAMETHASONE; LIPID; PIMECROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTRON MICROSCOPY; EPIDERMIS; HUMAN; HUMAN TISSUE; HYDRATION; LAMELLAR BODY; LIPID BILAYER; LONG TERM CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN WATER LOSS; STRATUM CORNEUM; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; EPIDERMIS; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; SKIN ABSORPTION; TACROLIMUS; WATER LOSS, INSENSIBLE;

EID: 65349153666     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.014     Document Type: Erratum

References (52)

1. Bos J.D., Kapsenberg M.L., and Smitt J.H. Pathogenesis of atopic eczema. Lancet 343 (1994) 1338-1341
2. Leung D.Y., and Bieber T. Atopic dermatitis. Lancet 361 (2003) 151-160
3. Morar N., Willis-Owen S.A., Moffatt M.F., and Cookson W.O. The genetics of atopic dermatitis. J Allergy Clin Immunol 118 (2006) 24-34
4. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38 (2006) 441-446
5. Weidinger S., Illig T., Baurecht H., Irvine A.D., Rodriguez E., Diaz-Lacava A., et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 118 (2006) 214-219
6. Ruether A., Stoll M., Schwarz T., Schreiber S., and Fölster-Holst R. Filaggrin loss-of-function variant contributes to atopic dermatitis risk in the population of Northern Germany. Br J Dermatol 155 (2006) 1093-1095
7. Weidinger S., Rodriguez E., Stahl C., Wagenpfeil S., Klopp N., Illig T., et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 127 (2007) 724-726
8. Elias P.M., Wood L.C., and Feingold K.R. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 10 (1999) 119-126
9. Elias P.M., and Feingold K.R. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 137 (2001) 1079-1081
10. Yoshiike T., Aikawa Y., Sindhvananda J., Suto H., Nishimura K., Kawamoto T., et al. Skin barrier defect in atopic dermatitis: increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline. J Dermatol Sci 5 (1993) 92-96
11. Fartasch M., Bassukas I.D., and Diepgen T.L. Disturbed extruding mechanism of lamellar bodies in dry non-eczematous skin of atopics. Br J Dermatol 127 (1992) 221-227
12. Sugarman J.L., Fluhr J.W., Fowler A.J., Bruckner T., Diepgen T.L., and Williams M.L. The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 139 (2003) 1417-1422
13. Seguchi T., Cui C.Y., Kusuda S., Takahashi M., Aisu K., and Tezuka T. Decreased expression of filaggrin in atopic skin. Arch Dermatol Res 288 (1996) 442-446
14. Jensen J.M., Fölster-Holst R., Baranowsky A., Schunck M., Winoto-Morbach S., Neumann C., et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 122 (2004) 1423-1431
15. Ogawa H., and Yoshiike T.J. A speculative view of atopic dermatitis: barrier dysfunction in pathogenesis. Dermatol Sci 5 (1993) 197-204
16. Proksch E., Jensen J.M., and Elias P.M. Skin lipids and epidermal differentiation in atopic dermatitis. Clin Dermatol 21 (2003) 134-144
17. Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 4 (2004) 978-988
18. Proksch E., Fölster-Holst R., and Jensen J.M. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 43 (2006) 159-169
19. Jakasa I., de Jongh C.M., Verberk M.M., Bos J.D., and Kezic S. Percutaneous penetration of sodium lauryl sulphate is increased in uninvolved skin of patients with atopic dermatitis compared with control subjects. Br J Dermatol 155 (2006) 104-109
20. Jakasa I., Verberk M.M., Esposito M., Bos J.D., and Kezic S. Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol 127 (2007) 129-134
21. Guillet G., and Guillet M.H. Natural history of sensitizations in atopic dermatitis: a 3-year follow-up in 250 children: food allergy and high risk of respiratory symptoms. Arch Dermatol 128 (1992) 187-192
22. Fölster-Holst R., Pape M., Buss Y.L., Christophers E., and Weichenthal M. Low prevalence of the intrinsic form of atopic dermatitis among adult patients. Allergy 61 (2006) 629-632
23. Allam J.P., and Novak N. The pathophysiology of atopic eczema. Clin Exp Dermatol 31 (2006) 89-93
24. Howell M.D., Kim B.E., Gao P., Grant A.V., Boguniewicz M., Debenedetto A., et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 120 (2007) 150-155
25. Stütz A., Baumann K., Grassberger M., Wolff K., and Meingassner J.G. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 141 (2006) 199-212
26. Meingassner J.G., Aschauer H., Stütz A., and Billich A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol 14 (2005) 752-757
27. Hoetzenecker W., Meingassner J.G., Ecker R., Stingl G., Stütz A., and Elbe-Bürger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 122 (2004) 673-684
28. Hashimoto-Kumasaka K., Takahashi K., and Tagami H. Electrical measurement of the water content of the stratum corneum in vivo and in vitro under various conditions: comparison between skin surface hygrometer and corneometer in evaluation of the skin surface hydration state. Acta Derm Venereol 73 (1993) 335-339
29. Pinnagoda J., Tupker R.A., Agner T., and Serup J. Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 22 (1990) 164-181
30. Tate M., Grove G., Joch R., Laabs J., Menard K., Nelson B., et al. Dye exclusion as a means to measure wetness protection of human skin. Skin Res Technol 13 (2007) 293-298
31. Hazelbag H.M., Laforga J.B., Roels H.J., and Hogendoorn P.C. Dedifferentiated adamantinoma with revertant mesenchymal phenotype. Am J Surg Pathol 27 (1995) 1530-1537
32. Elias P.M., and Friend D.S. The permeability barrier in mammalian epidermis. J Cell Biol 65 (1975) 180-191
33. Luft J.H. Improvements in epoxy resin embedding methods. J Biophys Biochem Cytol 9 (1961) 409-414
34. Reynolds E.S. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 17 (1963) 208-212
35. Agner T. Noninvasive measuring methods for the investigation of irritant patch test reactions. A study of patients with hand eczema, atopic dermatitis and controls. Acta Derm Venereol Suppl (Stockh) 173 (1992) 1-26
36. Elias P.M., Hatano Y., and Williams M.L. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 121 (2008) 1337-1343
37. Meingassner J.G., Kowalsky E., Schwendinger H., Elbe-Bürger A., and Stütz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 149 (2003) 853-857
38. Hengge U., Ruzicka T., Schwartz R.A., and Cork M.J. Adverse effects of topical glucocorticosteroids. Am Acad Dermatol 54 (2006) 1-15
39. Queille-Roussel C., Paul C., Duteil L., Lefebvre M.C., Rapatz G., Zagula M., et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 144 (2001) 507-513
40. Kim B.E., Leung D.Y., Boguniewicz M., and Howell M.D. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 126 (2008) 332-337
41. Scott I.R., and Harding C.R. Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. Dev Biol 115 (1986) 84-92
42. Tunggal J.A., Helfrich I., Schmitz A., Schwarz H., Günzel D., Fromm M., et al. E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions. EMBO J 24 (2005) 1146-1156
43. Kolbe L., Kligman A.M., Schreiner V., and Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 7 (2001) 73-77
44. Endo K., Suzuki N., Yoshida O., Sato H., and Fujikura Y. The barrier component and the driving force component of transepidermal water loss and their application to skin irritant tests. Skin Res Technol 13 (2007) 425-435
45. Aalto-Korte K. Improvement of skin barrier function during treatment of atopic dermatitis. J Am Acad Dermatol 33 (1995) 969-972
46. Zesch A., and Schaefer H. Penetration of radioactive hydrocortisone in human skin from various ointment bases. II. In vivo-experiments. [author's translation]. Arch Dermatol Forsch 252 (1975) 245-256
47. Elias P.M., and Menon G.K. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 24 (1991) 1-26
48. Sheu H.M., Lee J.Y., Chai C.Y., and Kuo K.W. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 136 (1997) 884-890
49. Kao J.S., Fluhr J.W., Man M.Q., Fowler A.J., Hachem J.P., Crumrine D., et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 120 (2003) 456-464
50. Stütz A., Grassberger M., and Meingassner J.G. Pimecrolimus (Elidel, SDZ ASM 981)-preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 20 (2001) 233-241
51. Luger T. Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 11 (2001) 343-347
52. Novak N., Kwiek B., and Bieber T. The mode of topical immunomodulators in the immunological network of atopic dermatitis. Clin Exp Dermatol 30 (2005) 160-164